ASPire To Win Provides Contract Research Organizations with Cost-Effective EDC and eCDM Capabilities to Increase Market Reach
ASPire To Win Provides Contract Research Organizations with Cost-Effective EDC and eCDM Capabilities to Increase Market Reach
New York, NY, April 4th, 2005 - Medidata Solutions Inc., a leading provider of electronic clinical data management solutions today announced ASPire To Win, the company's flagship partnership program for Contract Research Organizations (CROs). ASPire To Win is a non-exclusive, application service provider (ASP) partnership enabling CROs to implement and use Medidata RAVE for conducting electronic clinical trials. The program provides the training, certification and collaboration to equip CROs with the skills and capability to cost-effectively and professionally implement clinical trials using Medidata's electronic data capture (EDC) and electronic clinical data management (eCDM) technology.
Increasingly, drug sponsors require the use of EDC during clinical studies to streamline data collection and increase accuracy. This trend is growing as both drug sponsors and CROs have experienced the upside of EDC versus traditional paper-based approaches. Medidata has launched ASPire To Win to shift ASP service revenue related to EDC deployment away from the technology provider, and to the CRO that builds, implements, and manages the EDC study. During the sales cycle, CROs will benefit from adding EDC to their portfolio of services offerings; on the operations side, CROs will be knowledgeable and ready to implement EDC studies using Medidata RAVE.
"The ASPire To Win program leverages core competencies - our CRO partners will provide services and Medidata, an acknowledged leader in this field, will provide the intellectual property to support those services," said Dennis Cunningham, Senior Vice President of Strategic Alliances, Medidata. "ASPire To Win is a cost effective way for CROs to build a services business around Medidata RAVE's electronic data capture and electronic clinical data management technologies without any upfront technology transfer costs. We are experiencing significant adoption by CROs of Medidata's RAVE solution as both sponsors and CROs recognize the benefits of automation and our technology."
As part of the ASPire To Win program, CROs will be trained to build electronic Case Report Forms according to the study protocol and certified to implement EDC studies with full regulatory compliance. CROs will achieve core competency in edit specifications, outputs, data mining, and EDC administration, so that when a sponsor requests EDC in a clinical trial, certified CROs will be fully qualified to implement and manage electronic data capture using Medidata's industry-leading RAVE platform.
About Medidata Solutions
Medidata Solutions understands and helps clients manage the business of electronic clinical data management better than any one else. Designed to reduce the latency of information flow, optimize decision-making and improve resource allocation and safety, Medidata Solutions' flexible, enterprise-class workflow and web-based technology assists global life sciences and research organizations to accelerate the process of bringing life-enhancing treatments to market. Streamlined collection, verification, consolidation and analysis of clinical research data gives front line investigators, data managers and executives powerful tools to make more precise decisions earlier, reduce costs and drive efficiency. For more information about Medidata Solutions, visit www.mdsol.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
MariTide Shows Up to 20% Weight Loss in Phase II Trial for Obesity, Type 2 Diabetes
June 24th 2025In a Phase II trial, Amgen’s investigational therapy MariTide (maridebart cafraglutide) delivered significant, sustained weight loss of up to 20% in adults with obesity, with or without type 2 diabetes, alongside notable improvements in glycemic control, supporting its advancement to Phase III studies as a potential once-monthly treatment option.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.